You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Charles River Laboratories International, Inc. agreed to acquire Frontage Holdings Corporation’s bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470 million cash plus up to $75 million contingent payments; closing is expected during the first half of 2027.
Charles River Laboratories International, Inc. reported revenue of $982.7 million, down 2.2%, and operating income of $202.6 million. Net income attributable to common shareholders reached $333.1 million, helped by a $201 million tax benefit.
Charles River Laboratories reported third-quarter revenue of $982.7 million, 4.7% organic growth, and non-GAAP diluted EPS of $3.09. It raised 2026 organic revenue guidance to at least +1.5% and non-GAAP EPS guidance to $11.35 – $11.55.
Charles River reaffirmed 2026 revenue growth and non-GAAP EPS at the upper ends of 0% – 1% and $11.15 – $11.45, respectively, and set 2030 targets of 5% – 7% organic revenue CAGR and ~24% non-GAAP operating margin.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Charles River returned to organic revenue growth (0.1%) and beat prior EPS outlook, raising full-year organic revenue guidance by 150 bps and non-GAAP EPS by $0.25 at midpoint, driven by a sharp pickup in DSA bookings (net book-to-bill of 1.19x, highest in nearly four years).
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Capital expenditures | $31.11M | Three Months Ended June 27, 2026 | -11.9% |
|
|
|||
| Effective tax rate | 101.4% | the three months ended June 27, 2026 filing | — |
| Non-GAAP net income non-GAAP | $146.2M | second quarter of 2026 | — |
| Non-GAAP operating income as a % of revenue non-GAAP | 18.4% | Six Months Ended June 27, 2026 | — |
| Operating income, excluding non-GAAP adjustments non-GAAP | $368.31M | Six Months Ended June 27, 2026 | — |
|
|
|||
| Organic revenue growth non-GAAP | 0.1% | second quarter of 2026 | — |
| Restructuring costs | $23.1M | the three months ended June 27, 2026 filing | — |
| Revenue growth, reported | -2.7% | Three Months Ended June 27, 2026 | — |
| Shares repurchased under the stock repurchase program | 0.6M | the three months ended June 27, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRL
this stock
Charles River Laboratories International, Inc.
|
$16.19B | +69.4% | +10.5% | 352.1 | 6.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$259.44B | +20.8% | +14.5% | 36.9 | 1.3% |
|
DHR
Danaher Corp
|
$163.94B | +1.8% | +8.5% | 38.1 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.48B | +4.1% | +10.4% | 47.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.04B | +27.8% | +6.4% | 34.2 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Charles River Laboratories International, Inc. agreed to acquire Frontage Holdings Corporation’s bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470 million cash plus up to $75 million contingent payments; closing is expected during the first half of 2027.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRL | +0.1% | +12.6% | +115.6% | -6.0% | +69.4% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -2.5% | +13.8% | +115.1% | -5.8% | +58.8% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
